Neoral

(Cyclosporine)

ApprovedSmall molecule

Cyclosporine is used to prevent the body's immune system from rejecting transplanted organs like kidneys, heart, or liver, and also to treat severe autoimmune conditions like rheumatoid arthritis and certain eye diseases by suppressing overactive immune responses.[2] Neoral is currently approved and in use across 92 indications[4].[1]

Neoral is one of 1387 small molecule programs targeting Aplastic Anemia. It is currently in Approved.

Indications

405

Total Trials

Active Trials

1,386

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Aplastic AnemiaRecruiting

Hematological MalignanciesRecruiting

FibrosisActive, not recruiting

Ulcerative ColitisActive, not recruiting

Hepatitis CActive, not recruiting

Bronchiolitis ObliteransApproved

Acute Myocardial InfarctionApproved

Cardiac ArrestApproved

Myocardial InfarctionApproved

UveitisApproved

Aplastic AnemiaPhase 2

Recruiting

Hematological MalignanciesPhase 2

Recruiting

FibrosisApproved

Active, not recruiting

Ulcerative ColitisApproved

Active, not recruiting

Hepatitis CApproved

Active, not recruiting

Bronchiolitis ObliteransApproved

Approved

Acute Myocardial InfarctionApproved

Approved

Cardiac ArrestApproved

Approved

Myocardial InfarctionApproved

Approved

UveitisApproved

Approved

Showing 10 of 92 indications

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Neoral

Novartis

Approved

3 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Calciferol

Activella

Tricor

1 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 10

Benadryl

PParkedale

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Neuroblastoma

NCT05303727

Q4 2027

Phase 2Recruiting

Aplastic Anemia

NCT06752694

Q2 2028

Post-ApprovalNot yet recruiting

Efficacy and Safety

NCT06364319

Q1 2029

Phase 2Recruiting

Hematological Malignancies

NCT04195633

Clinical

Trials by Indication[1]

Kidney Transplant10 trials

Study Evaluating the Efficacy and Safety of Cyclosporine Reduction in Kidney Transplant Recipients Receiving Sirolimus

Completed· Pfizer logo

Pfizer·Phase 4·NCT00507793·385 enrolled

Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients

Withdrawn· Pfizer logo

Pfizer·Phase 2·NCT00556257

Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant Recipients

Completed· Pfizer logo

Pfizer·Phase 3·NCT00428064·408 enrolled

Show 7 more trials

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

Completed· Pfizer logo

Pfizer·Phase 2·NCT00658359·178 enrolled

Everolimus in de Novo Kidney Transplant Recipients

Completed· Novartis logo

Novartis·Phase 3·NCT01410448·383 enrolled

Study Evaluating Sirolimus in Kidney Transplant Recipients.

Completed· Pfizer logo

Pfizer·Phase 3·NCT00167947·150 enrolled

A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant

Terminated·—·Phase 3·NCT00005113·102 enrolled

Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00007787·350 enrolled

Study Evaluating Sirolimus in Kidney Transplant Recipients

Completed· Pfizer logo

Pfizer·Phase 3·NCT00195273·61 enrolled

Study Evaluating Cyclosporine Dose Reduction and Cyclosporine Elimination in Chinese Kidney Transplants

Completed· Pfizer logo

Pfizer·Phase 1/2·NCT00257387·120 enrolled

Lymphoma10 trials

Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00387959·17 enrolled

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT01434472·20 enrolled

Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00041288·10 enrolled

Show 7 more trials

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Unknown status·JJoseph Tuscano·Phase 2·NCT01811368·20 enrolled

Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Unknown status·UUniversity of California, Davis·Phase 1·NCT00008021

Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma

Withdrawn·AAIDS Malignancy Consortium·Phase 2·NCT00024128

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed·—·Phase 1·NCT03013933·29 enrolled

Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

Unknown status·UUniversity of California, Davis·Phase 1·NCT00009776

Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 3·NCT00003414·50 enrolled

Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00907036·49 enrolled

Stem Cell Transplant10 trials

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00006251·21 enrolled

Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00005941

Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

Withdrawn·UUniversity of Nebraska·Phase 1/2·NCT00816413

Show 7 more trials

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

Completed·FFred Hutchinson Cancer Center·N/A·NCT00112593·5 enrolled

Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00075478·87 enrolled

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

Completed·UUniversity of California, San Francisco·Phase 2·NCT00301834·35 enrolled

Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer

Terminated·UUniversity of California, San Francisco·N/A·NCT00301860·8 enrolled

Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers

Completed·UUniversity of California, Davis·Phase 2·NCT00619645·8 enrolled

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Withdrawn·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT00085449

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Completed·OOHSU Knight Cancer Institute·Phase 1/2·NCT00245037·147 enrolled

Bone Marrow Transplantation7 trials

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005852

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00303719·342 enrolled

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

Completed·—·Phase 1·NCT00005988·5 enrolled

Show 4 more trials

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005641

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00005854

Bone Marrow Transplantation in Treating Patients With Leukemia

Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 3·NCT00006451

Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders

Completed·FFred Hutchinson Cancer Center·N/A·NCT00010361·20 enrolled

Leukemia7 trials

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

Completed·RRobert Lowsky·Phase 2·NCT02424968·18 enrolled

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Terminated·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00066417·51 enrolled

Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00357565·34 enrolled

Show 4 more trials

Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation

Terminated·BBaxalta now part of Shire·Phase 3·NCT00003056·105 enrolled

Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00363779·5 enrolled

Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission

Completed·FFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium·Phase 2·NCT00031655·30 enrolled

Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00005940·18 enrolled

97 more indications

Acute Lymphoblastic Leukemia6 trials

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00022737·220 enrolled

Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

Completed·NNohla Therapeutics, Inc.·Phase 2·NCT01690520·163 enrolled

Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00022126·6 enrolled

Show 3 more trials

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00036738·28 enrolled

Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Unknown status·JJonsson Comprehensive Cancer Center·N/A·NCT00093587

Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia

Terminated·—·Phase 3·NCT00002961·43 enrolled

Acute Myeloid Leukemia5 trials

Cyclosporine and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Unknown status·UUniversity Medical Center Groningen·Phase 2·NCT00002688·25 enrolled

Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00089050

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00553202·158 enrolled

Show 2 more trials

Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy

Completed·CChildren's Oncology Group·Phase 2·NCT00070174·350 enrolled

Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

Completed·—·Phase 2·NCT01020734·263 enrolled

Graft Versus Host Disease5 trials

Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease

Completed·SSeoul National University Hospital·Phase 2/3·NCT01788501·50 enrolled

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT03970096·120 enrolled

Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant

Withdrawn·FFred Hutchinson Cancer Center·Phase 1/2·NCT00002790

Show 2 more trials

Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor

Completed· Astellas logo

Astellas·Phase 4·NCT02660684·39 enrolled

Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT

Completed·HHospital Universitario Dr. Jose E. Gonzalez·Phase 2·NCT02144025·21 enrolled

Severe Aplastic Anemia5 trials

Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure

Unknown status·FFederico II University·Phase 2·NCT00895739·50 enrolled

Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00260689·136 enrolled

Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT00354419·30 enrolled

Show 2 more trials

Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00343785·21 enrolled

Comparing Therapies for the Treatment of Severe Aplastic Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00001626·33 enrolled

Breast Cancer5 trials

Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01105650·13 enrolled

Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer

Unknown status·UUniversity of California, Davis·Phase 1·NCT00003920·18 enrolled

Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 3·NCT00008203

Show 2 more trials

Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

Unknown status·UUniversity of California, Davis·Phase 1·NCT00009763

Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020176

Myelodysplastic Syndrome4 trials

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00024050

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00119366·18 enrolled

S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome

Completed·SSWOG Cancer Research Network·Phase 2·NCT00016419·130 enrolled

Show 1 more trial

High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma

Completed·—·Phase 2·NCT01177371·13 enrolled

Hematological Malignancies4 trials

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01527045·47 enrolled

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT04195633·60 enrolled

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00040846·60 enrolled

Show 1 more trial

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01789255·12 enrolled

Aplastic Anemia4 trials

Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia

Completed· Novartis logo

Novartis·Phase 2·NCT02998645·54 enrolled

Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT06752694·20 enrolled

Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00005935·130 enrolled

Show 1 more trial

Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia

Unknown status·—·N/A·NCT00017654·3 enrolled

Chronic Myelogenous Leukemia4 trials

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01426334·4 enrolled

Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00110058·40 enrolled

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Withdrawn·—·Phase 1/2·NCT00002761

Show 1 more trial

Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00119340·75 enrolled

Hematologic Disease3 trials

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00376519·3 enrolled

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00719888·135 enrolled

Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Unknown status·CCancer Research UK·Phase 2·NCT00959231·60 enrolled

Interaction3 trials

Drug-Drug Interaction Study in Healthy Adult Volunteers

Completed·KKowa Research Institute, Inc.·Phase 1·NCT02276001·20 enrolled

A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT05573230·32 enrolled

Drug Interaction Study of Isavuconazole and Cyclosporine

Completed· Astellas logo

Astellas·Phase 1·NCT01494597·24 enrolled

Hematologic Cancer3 trials

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT00290628·43 enrolled

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003270·20 enrolled

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003661·3 enrolled

Myeloproliferative Disorder3 trials

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00397813·77 enrolled

Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00054340

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Completed·EEverett Meyer·Phase 2·NCT01392989·44 enrolled

Tacrolimus3 trials

Diabetogenicity of Cyclosporine and Tacrolimus

Completed·UUniversity of Aarhus·Phase 4·NCT00766909·18 enrolled

A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 1·NCT01479881·29 enrolled

Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens

Completed· Astellas logo

Astellas·Phase 3·NCT00157014·111 enrolled

Multiple Myeloma3 trials

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00014508

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00054353·16 enrolled

Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00006184·20 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD

Not yet recruiting·PPeking University People's Hospital·Phase 4·NCT06364319·118 enrolled

Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients

Completed· Novartis logo

Novartis·Phase 4·NCT00154310·300 enrolled

Kidney Cancer2 trials

Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00243009·1 enrolled

Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer

Completed·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT00006968·4 enrolled

Peripheral Blood Stem Cell Transplantation2 trials

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01427881·43 enrolled

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

Withdrawn·FFred Hutchinson Cancer Center·Phase 2·NCT03602898

Fanconi Anemia2 trials

Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00630253·31 enrolled

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00093743·2 enrolled

Atopic Dermatitis2 trials

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not yet recruiting·UUniversity of California, San Francisco·Phase 4·NCT07352566·10 enrolled

Dupilumab and House Dust Mite Immunotherapy in Patients With Atopic Dermatitis

Completed·MMedical University of Silesia·N/A·NCT06509243·132 enrolled

Liver Transplant2 trials

Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00105235·27 enrolled

Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation

Completed·UUniversity of Florida·Phase 4·NCT00821587·39 enrolled

Treatment2 trials

MSC for Treatment of cGVHD After Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2·NCT04692376·152 enrolled

Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment

Completed·PPeking University Third Hospital·Phase 4·NCT05294666·89 enrolled

Transplantation2 trials

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT03246906·150 enrolled

Allogeneic Transplantation From Related Haploidentical Donors

Completed·SStanford University·Phase 2·NCT00185692·16 enrolled

Chronic Lymphocytic Leukemia2 trials

Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00104858·66 enrolled

Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·N/A·NCT00003196·63 enrolled

Dry Eye Syndrome2 trials

Tear Film Markers in Dry Eye Syndrome

Withdrawn·VVishal Jhanji·Phase 4·NCT04515329

Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005)

Completed·SSirion Therapeutics, Inc.·Phase 3·NCT00502073

Hematologic Malignancies2 trials

Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

Completed·NNohla Therapeutics, Inc.·Phase 2·NCT01175785·15 enrolled

Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Completed·—·Phase 2·NCT01093586·14 enrolled

Allogeneic Stem Cell Transplantation2 trials

Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies

Completed·—·N/A·NCT00741455·18 enrolled

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00080925·20 enrolled

Myocarditis2 trials

Myocarditis Treatment Trial

Completed·UUniversity of Utah·Phase 2·NCT00000524

Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis

Completed·MMayo Clinic·N/A·NCT00027443·40 enrolled

COVID-191 trial

Cyclosporine For The Treatment Of COVID-19(+)

Completed·—·Phase 2·NCT04492891·47 enrolled

Dexamethasone1 trial

Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax

Completed·TThomas Chester, OD·Phase 4·NCT04555694·30 enrolled

Metastatic Prostate Cancer1 trial

Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Unknown status·UUniversity of California, Davis·Phase 1·NCT00009750

Bone Marrow Transplant1 trial

Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer

Active, not recruiting·—·Phase 2·NCT00534430·30 enrolled

Immunosuppressive Agents1 trial

Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients

Unknown status·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT03150134·100 enrolled

Adult Subject1 trial

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

Completed·EEnanta Pharmaceuticals, Inc·Phase 1·NCT03750383·48 enrolled

Stem Cell Transplantation1 trial

Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00044954

Natural Killer Cell1 trial

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00354172·16 enrolled

Renal Transplant Recipients1 trial

Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients

Completed· Roche logo

Roche·Phase 3·NCT02686619·237 enrolled

Hepatitis C1 trial

Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients

Completed·IIrmandade Santa Casa de Misericórdia de Porto Alegre·Phase 4·NCT01469884·30 enrolled

Drug Interactions1 trial

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05109390·72 enrolled

Phase 21 trial

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Terminated·SStanford University·Phase 2·NCT00482053·3 enrolled

Histiocytosis1 trial

Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00334672·288 enrolled

Immunosuppression1 trial

Phase I/II Thymus Transplantation With Immunosuppression #950

Completed·SSumitomo Pharma Switzerland GmbH·Phase 1/2·NCT00579527·14 enrolled

Tic Disorder1 trial

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

Unknown status·—·N/A·NCT00006056·40 enrolled

Experimental1 trial

An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03419910·54 enrolled

Medication1 trial

A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081

Completed· Roche logo

Roche·Phase 1·NCT06809608·36 enrolled

Cancer1 trial

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00796068·130 enrolled

Heart Transplant1 trial

SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance

Completed· Novartis logo

Novartis·Phase 4·NCT01266148·115 enrolled

Adult1 trial

A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.

Completed· Pfizer logo

Pfizer·Phase 1·NCT06541678·16 enrolled

Acute Graft Versus Host Disease1 trial

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

Completed·MMesoblast, Ltd.·Phase 2·NCT00136903·32 enrolled

Hematopoietic Cell Transplantation1 trial

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

Completed·UUniversity of Utah·Phase 2·NCT00795132·47 enrolled

Methotrexate1 trial

Drug-Drug Interaction of Rifampicin and Cyclosporine on Methotrexate Pharmacokinetics in Healthy Subjects

Active, not recruiting·SSeoul National University Bundang Hospital·Phase 1·NCT07196449·12 enrolled

Intravenous Administration1 trial

Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects

Completed·SSymBio Pharmaceuticals·Phase 1·NCT04542252·13 enrolled

Myelodysplasia1 trial

Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia

Completed·—·Phase 2·NCT00005937·42 enrolled

Myelodysplastic Syndromes1 trial

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00045305·17 enrolled

Angioimmunoblastic T-Cell Lymphoma1 trial

Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma

Terminated·EEastern Cooperative Oncology Group·Phase 2·NCT00070291·4 enrolled

Neuroblastoma1 trial

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05303727·64 enrolled

Sickle Cell Disease1 trial

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

Completed·MMonica Bhatia·Phase 1·NCT02867800·24 enrolled

Hematologic Disorder1 trial

Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders

Completed·—·Phase 2·NCT00636909·25 enrolled

Thrombotic Thrombocytopenic Purpura1 trial

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

Completed·OOhio State University·Phase 3·NCT00713193·26 enrolled

Colorectal Cancer1 trial

Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer

Completed·UUniversity of Chicago·Phase 2·NCT00003950·16 enrolled

Keratoconjunctivitis sicca1 trial

Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Completed· Sun Pharmaceutical Industries Limited logo

Sun Pharmaceutical Industries Limited·Phase 3·NCT02688556·745 enrolled

Myeloid Neoplasm1 trial

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

Completed·UUniversity of Washington·Phase 2·NCT02756572·30 enrolled

Lymphoproliferative Disorders1 trial

Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT00001533·25 enrolled

Effectiveness1 trial

Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital

Completed·—·Phase 3·NCT04979884·66 enrolled

Hospitalized Patients1 trial

Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19

Completed·IInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz·Phase 4·NCT04392531·111 enrolled

Advanced1 trial

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00719849·13 enrolled

ESS1 trial

Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01504906·20 enrolled

Surgical1 trial

Comparison of Effect of Postoperative Cyclosporine A 2% Ophthalmic Emulsion and Betamethasone Eye Drop on Surgical Success of Trabeculectomy Procedure

Completed·MMashhad University of Medical Sciences·Phase 2·NCT02114073·40 enrolled

Severe Combined Immunodeficiency1 trial

Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00008450·6 enrolled

Retinoblastoma1 trial

Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma

Active, not recruiting·TThe Hospital for Sick Children·Phase 2·NCT00110110·71 enrolled

T Cell1 trial

Methods of T Cell Depletion Trial (MoTD)

Unknown status·UUniversity of Birmingham·Phase 2·NCT04888741·400 enrolled

Leber hereditary optic neuropathy1 trial

Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy

Unknown status·UUniversity Hospital, Angers·Phase 2·NCT02176733·12 enrolled

Prevention1 trial

Aerosol Cyclosporine for Prevention of Lung Rejection

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00268515

Cytokine Release Syndrome1 trial

Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome

Unknown status·HHospital Universitario Dr. Jose E. Gonzalez·Phase 2·NCT04781803·32 enrolled

Immune1 trial

Increasing HAART-Induced Immune Restoration With Cyclosporine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00031070·40 enrolled

Withdrawal1 trial

Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.

Completed· Novartis logo

Novartis·Phase 3·NCT01023815·330 enrolled

Thalassemia1 trial

Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00029380·30 enrolled

Renal Transplant1 trial

Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF)

Completed· Astellas logo

Astellas·Phase 4·NCT00637143·107 enrolled

Membranous Nephropathy1 trial

A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy

Completed·BBeijing Mabworks Biotech Co., Ltd.·Phase 1/2·NCT05398653·94 enrolled

Acute Leukemia1 trial

Total Marrow Irradiation for Refractory Acute Leukemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00686556·12 enrolled

Psoriasis1 trial

Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis

Unknown status·UUniversity of Athens·Phase 4·NCT02144857·200 enrolled

Malignant Solid Tumors1 trial

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

Unknown status·MMilton S. Hershey Medical Center·Phase 1·NCT00436761·20 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

Withdrawn·NNationwide Children's Hospital·Phase 2·NCT00874315

Metastatic Colorectal Cancer1 trial

Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil

Completed·UUniversity of Leeds·Phase 3·NCT00389870·1,198 enrolled

GvHD1 trial

In-Vivo Activated T-Cell Depletion to Prevent GVHD

Terminated·IIndiana University·N/A·NCT00594308·10 enrolled

Juvenile Myelomonocytic Leukemia1 trial

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00609739·1 enrolled

Safety and Efficacy1 trial

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00035555·230 enrolled

Recurrent or Metastatic1 trial

Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

Completed·—·N/A·NCT00521430·30 enrolled

Chronic Granulomatous Disease1 trial

Completed·—·Phase 2·NCT00578643·15 enrolled

Lung Transplantation1 trial

Nordic Study in Cardiac and Lung Transplantation: Outcome in Relation to Cyclosporine Microemulsion C2 Levels

Completed· Novartis logo

Novartis·Phase 4·NCT00154193·190 enrolled

Immunodeficiency1 trial

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00553098·29 enrolled

Anemia1 trial

Medical Treatment for Diamond Blackfan Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00001749·25 enrolled

De Novo Renal Transplantation1 trial

A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation

Withdrawn· Roche logo

Roche·Phase 2/3·NCT00729768

Tics1 trial

A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01718652·18 enrolled

Recurrent or Refractory1 trial

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT04530487·1 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Oral Cyclosporine in Chronic Obstructive Pulmonary Disease

Completed·MMichael Donahoe·Phase 1/2·NCT00974142·43 enrolled

Unspecified2 trials

SCHEDULE Follow Up Visit 5-7 yr

Completed· Novartis logo

Novartis·Phase 4·NCT02864706·95 enrolled

A Study of the Correlation Between Pharmacokinetic and Pharmacodynamic Parameters of CellCept (Mycophenolate Mofetil).

Completed· Roche logo

Roche·Phase 2·NCT01292226·45 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 14, 1983

SANDIMMUNE

NDA NDA050573

Nov 14, 1983

SANDIMMUNE

NDA NDA050574

Mar 2, 1990

SANDIMMUNE

NDA NDA050625

Jul 14, 1995

NEORAL

NDA NDA050715

Jul 14, 1995

NEORAL

NDA NDA050716

Jul 14, 1995

NEORAL

NDA NDA050715

Mar 5, 1997

NEORAL

NDA NDA050716

Jun 19, 1997

NEORAL

NDA NDA050715

Jun 19, 1997

NEORAL

NDA NDA050716

Jan 30, 1998

NEORAL

NDA NDA050716

Mar 30, 1998

NEORAL

NDA NDA050715

Mar 30, 1998

NEORAL

NDA NDA050716

Jul 24, 1998

NEORAL

NDA NDA050716

Jul 27, 1998

NEORAL

NDA NDA050716

May 13, 1999

NEORAL

NDA NDA050716

Dec 21, 1999

NEORAL

NDA NDA050715

Dec 21, 1999

NEORAL

NDA NDA050716

Jun 30, 2000

NEORAL

NDA NDA050715

Oct 4, 2000

NEORAL

NDA NDA050716

Oct 4, 2000

NEORAL

NDA NDA050715

Nov 29, 2000

NEORAL

NDA NDA050716

May 3, 2001

NEORAL

NDA NDA050716

Jan 16, 2002

NEORAL

NDA NDA050715

Feb 22, 2002

NEORAL

NDA NDA050716

Apr 12, 2002

NEORAL

NDA NDA050716

Apr 12, 2002

NEORAL

NDA NDA050715

Jun 12, 2002

NEORAL

NDA NDA050715

Jun 12, 2002

NEORAL

NDA NDA050716

Jun 12, 2002

NEORAL

NDA NDA050716

Jun 12, 2002

NEORAL

NDA NDA050715

Sep 26, 2002

NEORAL

NDA NDA050715

Dec 23, 2002

RESTASIS

NDA NDA050790

Feb 6, 2004

NEORAL

NDA NDA050715

Feb 6, 2004

NEORAL

NDA NDA050716

Feb 6, 2004

NEORAL

NDA NDA050715

Feb 6, 2004

NEORAL

NDA NDA050716

Jul 19, 2005

NEORAL

NDA NDA050716

Jul 19, 2005

NEORAL

NDA NDA050715

Mar 6, 2006

NEORAL

NDA NDA050716

Mar 6, 2006

NEORAL

NDA NDA050715

Aug 1, 2007

NEORAL

NDA NDA050715

Aug 1, 2007

NEORAL

NDA NDA050716

Sep 24, 2009

NEORAL

NDA NDA050716

Sep 24, 2009

NEORAL

NDA NDA050715

Oct 8, 2009

NEORAL

NDA NDA050716

Oct 8, 2009

NEORAL

NDA NDA050715

Aug 30, 2012

NEORAL

NDA NDA050715

Aug 30, 2012

NEORAL

NDA NDA050716

May 2, 2013

NEORAL

NDA NDA050716

May 2, 2013

NEORAL

NDA NDA050715

Aug 29, 2013

NEORAL

NDA NDA050716

Mar 31, 2015

NEORAL

NDA NDA050716

Mar 31, 2015

NEORAL

NDA NDA050715

Aug 14, 2018

CEQUA

NDA NDA210913

Jun 23, 2021

VERKAZIA

NDA NDA214965

May 30, 2023

VEVYE

NDA NDA217469

Sep 26, 2023

NEORAL

NDA NDA050716

Sep 26, 2023

NEORAL

NDA NDA050715

Sources

References

[1]
ClinicalTrials.gov — 405 trial records for Cyclosporine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Neoral drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Cyclosporine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Cyclosporine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA050716). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Neoral. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cyclophilin a Modulator[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Novartis

Patent Landscape[6]

Patent Cliff

Nov 3, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8524779Jan 27, 2026

7973081Jan 27, 2026

9956289Jan 27, 2026

11612658Jan 27, 2026

9220694Jan 27, 2026

17 more patents

8298568Nov 3, 2027

9132071Jun 2, 2029

8614178Dec 13, 2030

8292129Feb 25, 2031

8561859Apr 16, 2032

10441630Aug 23, 2033

8980839Aug 23, 2033

9937225Aug 23, 2033

9676525Feb 7, 2034

9669974May 11, 2034

12496326Sep 29, 2036

11951153Feb 28, 2037

10918694Feb 28, 2037

10813976Sep 22, 2037

11154513Nov 20, 2038

11413323Oct 11, 2039

12059449Apr 1, 2042